is unlikely to confer any survival benefit, but is likely to improve local control only. 6, 7 Tumor stage, myometrial invasion, mitotic count, tumor size, involvement of surgical margins by the tumor, histologic grade and menopausal status have been reported to have prognostic significance in various studies. [8] [9] [10] However, these findings are still controversial.
The purpose of this study was to investigate the clinico- Patient characteristics are presented in Table 1 . The median age at the time of diagnosis was 43 years (range: 29-49 years). All patients were premenopausal. One patient (12.5%) was nulliparous and 7 (87.5%) had at least one child at the time of diagnosis. The median parity was 2 (range: 0-4).
The median gravidity was 4 (range: 1-9). None of the patients had a personal or familial history of ESS. All the patients, except one, were symptomatic. Four of seven patients in whom clinical data were known presented with vaginal bleeding, one presented with lower abdominal pain, one presented with vaginal discharge, and another had an enlarged years. [13] [14] [15] LGESS usually occurs in women younger than 50 years of age, and patients with high-grade ESS tend to be older than 50 years of age. 2, 13 However, women younger than 20 years of age, affected by low-grade or high-grade ESS, have been reported in the literature. 2, 9 In the present study, the median age was 43 years, which is similar to other reports. The most common presenting symptom in our patients was vaginal bleeding and lower abdominal pain, followed by vaginal discharge. Dilatation and curettage was the method which could be used to diagnose ESS before surgery, but none of the patients was diagnosed as having a malignancy by dilatation and curettage in our series.
Surgery has always been described as the most effective treatment for uterine sarcoma. 8 documented lymph node metastasis in only one (12%). 20 Another report showed that none the seven patients with ESS had lymph node involvement. 21 It is difficult to analyze the incidence of lymph node metastasis in patients with ESS, because the disease is a rarity, and the true value of a lymphadenectomy in ESS is unknown. However, the high recurrence rate may be due, in part, to occult lymph node metastastases, and patients with advanced ESS should undergo a lymphadenectomy. 22 In our series, since only one patient underwent a lymphadenectomy, the effect of this treatment could not be analyzed statistically.
The efficacy of adjuvant therapy in patients with ESS is still not proven. One study reported no difference in recurrence rates in patients receiving surgery with adjuvant therapy versus surgery alone. 6 In several studies, it was also suggested, that chemotherapy has not been proven to be effective in recurrent disease. 4, 5 Postoperative radiotherapy has been shown to reduce the central tumor, but not distal recurrences and it has not improved overall survival. 5, 6 Weitmann et al., 23 reported that the overall local control rate of adjuvant radiation therapy was 93.8% after 5 years, and concluded that surgery and adjuvant therapy were the most effective treatments for patients with ESS, due to the excellent local control in all stages. Reeds 7 also suggested that pelvic radiation is unlikely to confer any survival benefit, but is likely to improve local control only. Our results revealed that adjuvant chemotherapy had no influence on the outcome of the disease. Since none of our patients was treated with radiotherapy and hormonal therapy, the possible role of this therapy could not be determined.
In most cases, the overall survival rates for patients suffering from uterine sarcomas are poor. However, a higher survival probability for patients with LGESS compared to other uterine sarcomas is often reported. 24, 25 In the present study, the 5-year overall survival was 100%. This finding is superior to the survival rates reported by Haberal and colleagues, 9 who observed an overall survival rate of 92%.
Bodner et al., 8 reported that early tumor stage, low myometrial invasion, and low mitotic count, were associated with a lengthened overall survival in patients with ESS. In another study, free resection margins at primary surgery, malignancy grade, tumor diameter, and menopausal status were important prognostic factors either in univariate or multivariate analyses. 10 However, Haberal et al., 9 suggested that tumor grading was the only prognostic factor in ESS in a multivariate analysis.
Clinical characteristics of Stage I LGESS include a slow
growth and indolent disease course with a tendency for late recurrence. In one large series, the intervals before recurrence varied from 3 months to 23 years, with a median interval of 3 years. 26 Styron et al., 27 described the case of a patient with LGESS, who experienced multiple recurrences during 29 years of follow-up. About 32-60% of patients with ESS experience a recurrence after the initial treatment. 2, 8, 9 Haberal et al., 9 reported that eight of 25 patients (32%) had a recurrence: three patients had a recurrence limited to the pelvis, three patients had pulmonary metastases, one had a recurrence in the abdomen, and one in the brain.
Relapses occurred mainly in the pelvis, peritoneal cavity, and vagina; and less frequently in the lung, bowel, bones, and brain. 2, 8, 9 In our study, we found that one of 8 patients (12.5%) had a recurrence, which occurred in the lung after 7 years.
In conclusion, we found that patients with stage I LGESS had a very excellent prognosis. Additional studies, including prospective studies with larger numbers of patients, are necessary to define the exact role of lymphadenectomy and to determine the prognostic factors associated with LGESS.
